Grupos Investigadores

Miembros del Grupo

Coordinador
García Velloso, María José
(mjgarciave@unav.es)
Investigadores
Josep María
Marti Climent
José Ángel
Richter Echevarria
Lidia
Sancho Rodriguez
Colaboradores
Fabiana Lucrecia
Grisanti Vollbracht
María Isabel
Morales Lozano
Verónica
Morán Velasco

Líneas de Investigación

  • Dosis recibida por el paciente en estudios PET/CT
  • Dosis recibida por el paciente en exploraciones PET/CT
  • Imagen molecular en pacientes con amiloidosis cardíaca
  • Imagen molecular en pacientes con enfermedad inflamatoria arterial
  • Imagen molecular en pacientes con FOD / infección de prótesis
  • Imagen molecular en pacientes con linfoma
  • Imagen molecular en pacientes con tumores de células plasmáticas
  • Imagen molecular en pacientes con tumores de mama
  • Imagen molecular en pacientes con tumores de próstata
  • Imagen molecular en pacientes con tumores de pulmón
  • Imagen molecular en pacientes con tumores hepáticos

Palabras Clave

  • Amyloidosis
  • Breast
  • Choline
  • FDG
  • Fluoride
  • Infection
  • Inflammation
  • Lung
  • Methionine
  • Myeloma
  • PET
  • Prostate
  • Tumor

Publicaciones Científicas desde 2018

  • Autores: Morales Lozano, María Isabel; García Velloso, María José (Autor de correspondencia)
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.42 N° 2 2023 págs. 129 - 135
    Resumen
    Multiple myeloma is a monoclonal gammopathy, a clonal proliferative disorder of plasma cells that produces a protein called M or myeloma protein in the bone marrow, usually IgG or IgA. It accounts for 1% in the general cancer statistics and represents 10% of all hematologic tumours, with a cumulative incidence in Spain of about 5/100,000/year. The incidence increases with age, so that 50% of cases are diagnosed in patients over 75 years of age, being infrequent in the population under 40 years of age. This publication details the indications of FDG PET/CT for the staging and response assessment in patients with MM, accepted by the international working group on myeloma, as well as new molecular imaging radiopharmaceuticals with potential value for personalised medicine.
  • Autores: Bronte Viedma, Angela (Autor de correspondencia); Menendez Sanchez, Sandra; Bastidas Tamayo, Juan Fernando; et al.
    Revista: CLINICAL NUCLEAR MEDICINE
    ISSN: 0363-9762 Vol.48 N° 11 2023 págs. e526 - e528
    Resumen
    A 52-year-old man suffering left pleuritic pain underwent a chest CT showing a subpleural pulmonary nodule in the left upper lobe. Because of the possibility of a lung tumor, he was referred for 18 F-FDG PET/CT. The scan revealed FDG uptake in the pulmonary nodule, in an upper right paratracheal lymph node, and at 4 destructive bone lesions. Pathologic examination after pulmonary biopsy manifested only the presence of inflammatory cells. Further clinical history research proved risky sexual behavior with a positive syphilis serology test. A follow-up PET/CT 7 months after penicillin therapy showed a complete metabolic response of all the lesions.
  • Autores: Prieto Azcárate, Elena; Irazola Rosales, Leticia; Collantes Martínez, María; et al.
    Revista: SCIENTIFIC REPORTS
    ISSN: 2045-2322 Vol.12 N° 1 2022 págs. 18161
    Resumen
    The aim was to study the performance of the U-SPECT6/CT E-class system for preclinical imaging, to later demonstrate the viability of simultaneous multi-animal and multi-isotope imaging with reliable quantitative accuracy. The performance of the SPECT was evaluated for two collimators dedicated for mouse (UHS-M) and rat imaging (UHR-RM) in terms of sensitivity, energy resolution, uniformity and spatial resolution. Point sources, hot-rod and uniform phantoms were scanned, and additional tests were carried out to evaluate singular settings such as simultaneous multi-isotope acquisition and imaging with a multi-bed system. For in-vivo evaluation, simultaneous triple-isotope and multi-animal studies were performed on mice. Sensitivity for Tc-99m was 2370 cps/MBq for the UHS-M collimator and 493 cps/MBq for the UHR-RM. Rods of 0.6 mm and 0.9 mm were discernible with the UHS-M and UHR-RM collimators respectively, with optimized reconstruction. Uniformity in low counting conditions has proven to be poor (> 75%). Multi-isotope and multi-bed phantom acquisitions demonstrated accurate quantification. In mice, simultaneous multi-isotope imaging provided the separate distribution of 3 tracers and image quality of the multi-mouse bone scan was adequate. The U-SPECT6/CT E-class has shown good sensitivity and spatial resolution. This system provides quantitative images with suitable image quality for multi-mouse and multi-isotope acquisitions.
  • Autores: Boria Alegre, Félix; Chiva de Agustín, Luis (Autor de correspondencia); Carbonell, M.; et al.
    Revista: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    ISSN: 1048-891X Vol.32 N° 11 2022 págs. 1427 - 1432
    Resumen
    Objective: To assess the value of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan, combined with clinical variables, in predicting complete cytoreduction in selected patients with advanced ovarian cancer. Methods: We carried out a multicenter, observational, retrospective study evaluating patients who underwent primary cytoreductive surgery for advanced ovarian cancer in two Spanish centers between January 2017 and January 2022. Inclusion criteria were histological confirmation of invasive epithelial ovarian carcinoma; preoperative International Federation of Gynecology and Obstetrics (FIGO) stage III or IV; upfront cytoreductive surgery; and 18F-FDG PET/CT performed 1 month prior to surgery. A modified 18F-FDG PET/CT peritoneal cancer index score was calculated for all patients. Clinical variables and preoperative 18F-FDG PET/CT findings were analyzed and a multivariate model was constructed. A predictive score based on the odds ratio of the variables was calculated to determine patient selection. Results: A total of 45 patients underwent primary cytoreductive surgery. Complete resection was achieved in 36 (80%) patients. On multivariate analysis, two clinical variables (age ¿58 years and American Society of Anesthesiology score ¿3) and two preoperative 18F-FDG PET/CT scan findings (presence of extra-abdominal lymph node involvement and modified peritoneal cancer index value of 6 or more) were associated with gross residual disease. For this multivariate model predictive of non-complete cytoreduction, the area under the curve was 0.881. A predictive value of ¿5 was the most predictive cut-off for gross residual disease. Complete resection rate was 91.7% in patients with a score of ¿4 and 33.3% in patients with a score of ¿5 points on the predictive score. Conclusions: In selected patients, a predictive score value ¿5 may be consider as a cut-off point for triaging patients to diagnostic laparoscopy before the primary surgery or neoadjuvant chemotherapy.
  • Autores: Bronte Viedma, Angela (Autor de correspondencia); Rosales Castillo, Juan Jose; Bastidas Tamayo, Juan Fernando; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.41 N° Supl. 1 2022 págs. S48 - S50
  • Autores: Aldasoro, V.; García Velloso, María José; Richter Echevarria, José Ángel
    Revista: ANNALS OF THE RHEUMATIC DISEASES
    ISSN: 0003-4967 Vol.81 N° Suppl. 1 2022 págs. 1429 - 1429
  • Autores: Betech Antar, Vicky; Montijano, M. C.; Bronte Viedma, Angela; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.49 N° SUPPL 1 2022 págs. S412 - S413
  • Autores: Sancho Rodriguez, Lidia; Chiva de Agustín, Luis; Boria Alegre, Félix; et al.
    Revista: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    ISSN: 1048-891X Vol.32 N° Suppl. 2 2022 págs. A260
  • Autores: Cuenca Bandin, Teresa; Prieto Azcárate, Elena; Irazola Rosales, Leticia; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.49 N° Supl. 1 2022 págs. S594
  • Autores: Sancho Rodriguez, Lidia; Boria Alegre, Félix; Sánchez Lorenzo, María Luisa; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.49 N° Supl. 1 2022 págs. S516 - S517
  • Autores: Betech Antar, Vicky; Mínguez Lanzarote, Fernando; Bronte Viedma, Angela; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.49 N° Supl. 1 2022 págs. S457 - S458
  • Autores: Cuenca Bandin, Teresa; Prieto Azcárate, Elena; Irazola Rosales, Leticia; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.49 N° Supl. 1 2022 págs. S163 - S164
  • Autores: Marti Climent, Josep María; Martin, C. J.; Demeter, S.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.49 N° Supl. 1 2022 págs. S37
  • Autores: Leon-Mateos, L.; García Velloso, María José (Autor de correspondencia); Garcia-Figueiras, R.; et al.
    Revista: CLINICAL AND TRANSLATIONAL ONCOLOGY
    ISSN: 1699-048X Vol.23 N° 3 2021 págs. 434 - 449
    Resumen
    The implementation of immunotherapy has radically changed the treatment of oncological patients. Currently, immunotherapy is indicated in the treatment of patients with head and neck tumors, melanoma, lung cancer, bladder tumors, colon cancer, cervical cancer, breast cancer, Merkel cell carcinoma, liver cancer, leukemia and lymphomas. However, its efficacy is restricted to a limited number of cases. The challenge is, therefore, to identify which subset of patients would benefit from immunotherapy. To this end, the establishment of immunotherapy response criteria and predictive and prognostic biomarkers is of paramount interest. In this report, a group of experts of the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Medical Radiology (SERAM), and Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM) provide an up-to-date review and a consensus guide on these issues.
  • Autores: Bronte Viedma, Angela (Autor de correspondencia); Bastidas Tamayo, Juan Fernando; Rosales Castillo, Juan Jose; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.40 N° 6 2021 págs. 351 - 357
    Resumen
    Objetive: To evaluate the enterohepatic circulation of 75-Selenium turoselecolic acid (Se-75-SeHCAT) during the first 3 hours and its correlation with the abdominal retention at the 7th day (AR(7)), as contribution to the clinical study of biliar acid malabsorption (BAM). Materials and methods: 38 patients with chronic diarrhea were retrospectively studied. Acquisition protocol included static abdominal images at 1st , 2nd an d 3rd hour and the 7th day after oral administration of the radiopharmaceutical. Images of 1 to 3 hours determined 5 patterns of enterohepatic circulation that, due to their location, were characterized as: 1) gallbladder 2-3 hours, 2) gallbladder 3 hours, 3) gallbladder-abdomen 2-3 hours, 4) abdomen, 5) upper left abdomen. The association of these patterns with the AR(7) (Fisher, STATA) were investigated. Patients were classified as Non BAM (AR(7) >15%), mild-BAM (AR(7) : 15-10%), moderate-RAM (AR(7): 10-5%) or severe-BAM (AR(7) <5%). Results: 19 patients had an AR(7) diagnostic of BAM (7 mild-BAM, 5 moderate-RAM, 7 severe-BAM). The pattern gallbladder at 2-3 hours was statistically associated with Non BAM (p 0,008), while gallbladder-abdomen at 2-3 hours was correlated with having BAM (p 0,029). Conclusion: Variations detected at the abdominal level in images during the first 3 hours were associated with changes in intestinal absorption and the incorporation of the radiopharmaceutical into the pool of bile acids, so visual interpretation of the images at 2nd and 3rd hour could be useful in the final assessment of the study.
  • Autores: Grisanti Vollbracht, Fabiana Lucrecia (Autor de correspondencia); Zulueta Frances, Javier Joseph; Rosales Castillo, Juan Jose; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.40 N° 3 2021 págs. 155 - 160
    Resumen
    Objective; To determine the accuracy of visual analysis and the retention index (RI) with dual-time point (18)FFDG PET/CT for the characterization of indeterminate pulmonary nodules (IPN) with low FDG uptake. Materials and methods: A retrospective analysis was performed on 43 patients (28 men, 64 +/- 11 years old, range 36-83 years) referred for IPN characterization with F-18-FDG-PET/CT and maximum standard uptakevalue <= 2.5 at 60 minutes post-injection (SUVmax1). Nodules were analyzed by size, visual score for FDGuptake on standard (OSEM 2,8) and high definition (HD) reconstructions, SUVmax1, SUVmaxat 180 minutespostinjection (SUVmax2), and RI was calculated. The definitive diagnosis was based on histopathologicalconfirmation (n = 28) or >= 2 years of follow-up. Results: Twenty-four (56%) nodules were malignant. RI >= 10% on standard reconstruction detected 18nodules that would have been considered negative using the standard SUVmax >= 2.5 criterion for malignancy. RI >= 10% had a sensitivity, specificity, PPV, NPV and accuracy of 75, 73.7, 78.3, 70, and 74.4%, respectively, while for FDG uptake > liver on HD these were 79.1, 63.2, 73.1, 70.6, and 72.1%, respectively. SUVmax1 >= 2, SUVmax2 > 2.5 and FDG uptake > liver on standard reconstruction had a PPV of 100%. FDGuptake > mediastinum on HD had a NPV of 100%.
  • Autores: Rosales Castillo, Juan Jose (Autor de correspondencia); García Tobar, Laura; Bastidas Tamayo, Juan Fernando; et al.
    Revista: CLINICAL NUCLEAR MEDICINE
    ISSN: 0363-9762 Vol.46 N° 2 2021 págs. e127 - e128
    Resumen
    A 75-year-old man presented with dyspnea for more than 2 months, with blood test showing low platelet count and cardiac ultrasound showing severe pulmonary hypertension (>54 mm Hg). A CT pulmonary angiogram showed a filling defect in the pulmonary trunk, right and left pulmonary arteries, raising the possibilities of pulmonary embolism or artery sarcoma. FDG PET/CT was performed for further evaluation and showed low uptake in the pulmonary wall, which supported the diagnosis of pulmonary embolism. Patient was treated with anticoagulants with no changes on repeated CT pulmonary angiogram. Patient underwent surgery, and histopatological examination revealed a pulmonary artery sarcoma.
  • Autores: Simo-Perdigo, M. (Autor de correspondencia); Vercher-Conejero, J. L.; Viteri, S.; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.40 N° 2 2021 págs. 123 - 135
    Resumen
    The treatment of cancer by immunotherapy has been a revolution, as it is the first strategy that manages to control the disease for prolonged periods of time. Its efficacy is associated with different imaging response patterns and the appearance of new toxicities. We would highlight two patterns of tumour response: pseudoprogression, or growth of tumour lesions after the start of immunotherapy treatment, followed by a significant reduction in lesions, and hyperprogression, acceleration of tumour progression and metastasis early after the start of treatment. The emergence of such patterns has generated new metabolic response criteria, such as PECRIT, PERCIMT, imPERCIST and IPERCIST. Of particular interest are the new immunoPET-specific biomarkers, as they allow the identification of patients presenting the tumour target and are useful for predicting response to immunotherapy.
  • Autores: Perdomo Zelaya, Carolina María; García Goñi, Marta; Sancho Rodriguez, Lidia; et al.
    Revista: CLINICAL ENDOCRINOLOGY
    ISSN: 0300-0664 Vol.94 N° 3 2021 págs. 466 - 472
    Resumen
    Objective: A differential diagnosis of thyrotoxicosis is crucial as the treatment of the main causes of this condition can vary significantly. Recently published diagnostic guidelines on thyrotoxicosis embrace the presence of thyrotropin receptor (TSH-R) antibodies (TRAb) as the primary and most important diagnostic step. The application of diagnostic algorithms to aid in the treatment of hyperthyroidism supports using thyroid radionuclide scintigraphy (TRSt) in baffling clinical scenarios, when TRAb are absent or when third-generation TRAb are not available. First-generation TRAb measurement may have limitations. Consequently, patients with thyrotoxicosis and first-generation TRAb results may be misdiagnosed and consequently improperly treated. Our purpose was to compare first-generation TRAb values to TRSt in the differential diagnosis of hyperthyroidism. Methods: We conducted a retrospective study of 201 untreated outpatients with overt or subclinical hyperthyroidism on whom first-generation TRAb and TRSt had been performed at the time of diagnosis. Histological specimens were analysed in patients who had previously undergone thyroid surgery at our centre. SPSS 20.0 was used in statistical analysis. Results: Seventy-three out of 201 (36.3%) patients had positive TRAb. A diffuse uptake was present in 83.5% (61/73), whereas 13.7% (10/73) had a heterogeneous uptake and 2.7% (2/73) had an absent uptake. Thirty out of 91 (33%) patients with diffuse uptake were negative for positive TRAb and were diagnosed with Graves' disease. Analysis of 37 histological specimens indicated that TRSt had greater accuracy (81% vs 75.7%) and specificity (79.2% vs 57.1%) when compared to TRAb in the differential diagnosis of thyrotoxicosis. However, TRSt sensitivity was inferior to TRAb (84.6% vs 92.3%). Conclusions: Our study endorses that initial differential diagnosis of thyrotoxicosis should not be based solely on first-generation TRAb as this approach may leave nearly 20% of the patients misdiagnosed and, consequently, improperly treated. Our results underscore that thyroid scintigraphy should also be performed when only first-generation TRAb assays are available during the initial differential diagnosis of thyrotoxicosis.
  • Autores: Irazola Rosales, Leticia; Prieto Azcárate, Elena; Collantes Martínez, María; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.48 N° Supl. 1 2021 págs. S420 - S421
  • Autores: Marti Climent, Josep María
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.39 N° 3 2020 págs. 135 - 137
  • Autores: Morán Velasco, Verónica; Prieto Azcárate, Elena; Sancho Rodriguez, Lidia; et al.
    Revista: EJNMMI PHYSICS
    ISSN: 2197-7364 Vol.7 N° 1 2020 págs. 72
    Resumen
    Background Prior radioembolization, a simulation using Tc-99m-macroaggregated albumin as Y-90-microspheres surrogate is performed. Gamma scintigraphy images (planar, SPECT, or SPECT-CT) are acquired to evaluate intrahepatic Y-90-microspheres distribution and detect possible extrahepatic and lung shunting. These images may be used for pre-treatment dosimetry evaluation to calculate the Y-90 activity that would get an optimal tumor response while sparing healthy tissues. Several dosimetry methods are available, but there is still no consensus on the best methodology to calculate absorbed doses. The goal of this study was to retrospectively evaluate the impact of using different dosimetry approaches on the resulting Y-90-radioembolization pre-treatment absorbed dose evaluation based on Tc-99m-MAA images. Methods Absorbed doses within volumes of interest resulting from partition model (PM) and 3D voxel dosimetry methods (3D-VDM) (dose-point kernel convolution and local deposition method) were evaluated. Additionally, a new "Multi-tumor Partition Model" (MTPM) was developed. The differences among dosimetry approaches were evaluated in terms of mean absorbed dose and dose volume histograms within the volumes of interest. Results Differences in mean absorbed dose among dosimetry methods are higher in tumor volumes than in non-tumoral ones. The differences between MTPM and both 3D-VDM were substantially lower than those observed between PM and any 3D-VDM. A poor correlation and concordance were found between PM and the other studied dosimetry approaches. DVH obtained from either 3D-VDM are pretty similar in both healthy liver and individual tumors. Although no relevant global differences, in terms of absorbed dose in Gy, between both 3D-VDM were found, important voxel-by-voxel differences have been observed. Conclusions Significant differences among the studied dosimetry approaches for Y-90-radioembolization treatments exist. Differences do not yield a substantial impact in treatment planning for healthy tissue but they do for tumoral liver. An individual segmentation and evaluation of the tumors is essential. In patients with multiple tumors, the application of PM is not optimal and the 3D-VDM or the new MTPM are suggested instead. If a 3D-VDM method is not available, MTPM is the best option. Furthermore, both 3D-VDM approaches may be indistinctly used.
  • Autores: Morales Lozano, María Isabel; Viering, O.; Samnick, S.; et al.
    Revista: CANCERS
    ISSN: 2072-6694 Vol.12 N° 4 2020 págs. 1042
    Resumen
    11C-methionine (11C-MET) is a new positron emission tomography (PET) tracer for the assessment of disease activity in multiple myeloma (MM) patients, with preliminary data suggesting higher sensitivity and specificity than 18F-fluorodeoxyglucose (18F-FDG). However, the value of tumor burden biomarkers has yet to be investigated. Our goals were to corroborate the superiority of 11C-MET for MM staging and to compare its suitability for the assessment of metabolic tumor burden biomarkers in comparison to 18F-FDG. Twenty-two patients with newly diagnosed, treatment-naïve symptomatic MM who had undergone 11C-MET and 18F-FDG PET/CT were evaluated. Standardized uptake values (SUV) were determined and compared with total metabolic tumor volume (TMTV) for both tracers: total lesion glycolysis (TLG) and total lesion 11C-MET uptake (TLMU). PET-derived values were compared to Revised International Staging System (R-ISS), cytogenetic, and serologic MM markers such as M component, beta 2 microglobulin (B2M), serum free light chains (FLC), albumin, and lactate dehydrogenase (LDH). In 11 patients (50%), 11C-MET detected more focal lesions (FL) than FDG (p < 0.01). SUVmax, SUVmean, SUVpeak, TMTV, and TLMU were also significantly higher in 11C-MET than in 18F-FDG (p < 0.05, respectively). 11C-MET PET biomarkers had a better correlation with tumor burden (bone marrow plasma cell infiltration, M component; p < 0.05 versus p = n.s. respectively). This pilot study suggests that 11C-MET PET/CT is a more sensitive marker for the assessment of myeloma tumor burden than 18F-FDG. Its implications for prognosis evaluation need further investigation.
  • Autores: Marti Climent, Josep María
    Revista: NUCLEAR ESPAÑA
    ISSN: 2660-8715 Vol.Mayo 2020 págs. 2 - 8
  • Autores: García Velloso, María José; Peñuelas Sánchez, Iván; Ponz Sarvisé, Mariano; et al.
    Revista: JOURNAL FOR IMMUNOTHERAPY OF CANCER
    ISSN: 2051-1426 Vol.8 2020 págs. A175 - A175
  • Autores: Caresia-Aroztegui, A. P.; Delgado-Bolton, R. C.; Alvarez-Ruiz, S.; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.38 N° 1 2019 págs. 59 - 68
    Resumen
    Cervical cancer is the second most common gynecological cancer worldwide. In locally advanced cervical cancer, F-18-FDG PET/CT has become important in the initial staging, particularly in the detection of nodal and distant metastasis, aspects with treatment implications and prognostic value. The aims of this study were to review the role of F-18-FDG PET/CT in uterine cervical cancer, according to the guidelines of the main scientific institutions (FIGO, NCCN, SEGO, SEOM, ESGO, and ESMO) and its diagnostic accuracy compared to conventional radiological techniques, as well as to review the acquisition protocol and its utility in radiotherapy planning, response assessment and detection of recurrence.
  • Autores: Reynes-Llompart, G. ; Sabate-Llobera, A. ; Llinares-Tello, E.; et al.
    Revista: SCIENTIFIC REPORTS
    ISSN: 2045-2322 Vol.9 2019 págs. 10640
    Resumen
    The present work investigates the influence of different biological and physical parameters on image quality (IQ) perception of the abdominal area in a modern PET scanner, using new reconstruction algorithms and testing the utility of a radiomics approach. Scans of 112 patients were retrospectively included. Images were reconstructed using both OSEM + PSF and BSRM methods, and IQ of the abdominal region was subjectively evaluated. First, 22 IQ related parameters were obtained (including count rate and biological or mixed parameters) and compared to the subjective IQ scores by means of correlations and logistic regression. Second, an additional set of radiomics features was extracted, and a model was constructed by means of an elastic-net regression. For the OSEM + PSF and especially for the BSRM reconstructions, IQ parameters presented only at best moderated correlations with the subjective IQ. None of the studied parameters presented a good predictive power for IQ, while a simple radiomics model increased the performance of the IQ prediction. These results suggest the necessity of changing the standard parameters to evaluate IQ, particularly when a BSRM algorithm is involved. Furthermore, it seems that a simple radiomics model can outperform the use of any single parameter to assess IQ.
  • Autores: Morán Velasco, Verónica; Prieto Azcárate, Elena; Sancho Rodriguez, Lidia; et al.
    Revista: REVISTA DE FÍSICA MÉDICA
    ISSN: 1576-6632 Vol.20 N° 1 2019 págs. 31 - 53
  • Autores: Caresia-Aroztegui, A. P. (Autor de correspondencia); Delgado-Bolton, R. C. ; Alvarez-Ruiz, S.; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.38 N° 1 2019 págs. 59 - 68
    Resumen
    Cervical cancer is the second most common gynecological cancer worldwide. In locally advanced cervical cancer, F-18-FDG PET/CT has become important in the initial staging, particularly in the detection of nodal and distant metastasis, aspects with treatment implications and prognostic value. The aims of this study were to review the role of F-18-FDG PET/CT in uterine cervical cancer, according to the guidelines of the main scientific institutions (FIGO, NCCN, SEGO, SEOM, ESGO, and ESMO) and its diagnostic accuracy compared to conventional radiological techniques, as well as to review the acquisition protocol and its utility in radiotherapy planning, response assessment and detection of recurrence.
  • Autores: Rodríguez Fraile, María Macarena; Morales, M. ; Ezponda Casajús, Ana; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.46 N° SUPPL 1 2019 págs. S481 - S482
  • Autores: Marti Climent, Josep María; Prieto Azcárate, Elena; Aguilar Redondo, Pedro Borja; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.46 N° SUPPL 1 2019 págs. S772 - S772
  • Autores: Morán Velasco, Verónica; Aguilar Redondo, Pedro Borja; Prieto Azcárate, Elena; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.46 N° SUPPL 1 2019 págs. S830 - S830
  • Autores: Grisanti Vollbracht, Fabiana Lucrecia; Morales Lozano, María Isabel; Rosales Castillo, Juan Jose; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.46 N° SUPPL 1 2019 págs. S488 - S489
  • Autores: Guillen Valderrama, Edgar Fernando; Sancho Rodriguez, Lidia; Morán Velasco, Verónica; et al.
    Revista: JOURNAL OF NUCLEAR MEDICINE
    ISSN: 0161-5505 Vol.60 2019
  • Autores: Prieto Azcárate, Elena; Aguilar Redondo, Pedro Borja; Morán Velasco, Verónica; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.46 N° SUPPL 1 2019 págs. S838 - S838
  • Autores: Orduz, L. S.; Morales Lozano, María Isabel; Aradas-Cabado, B.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.46 N° SUPPL 1 2019 págs. S534 - S534
  • Autores: Orcajo-Rincon, J.; Caresia-Arortegui, A. P. (Autor de correspondencia); Cozar-Santiago, M. D. ; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.37 N° 5 2018 págs. 330 - 337
    Resumen
    Bone metastatic disease is the main cause of morbidity / mortality in patients with prostate cancer, presenting frequently as bone pain, pathological fractures or spinal cord compression, which requires early and timely therapy. Although, for the moment, the therapeutic window for its use has not been definitively established, radium-223 (Ra-223), an alpha particle emitter, has proved to be an effective therapeutic tool, pre or post-chemotherapy, in patients with castration-resistant prostate cancer with symptomatic bone metastases and absence of visceral metastases, significantly modifying the prognosis of the disease. It is therefore imperative to define the ideal scenarios and the correct protocol for the use of this therapy and thus offer the greatest possible clinical benefit to the patient. (C) 2018 Sociedad Espanola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espana, S.L.U. All rights reserved.
  • Autores: García Garzón, J. R. (Autor de correspondencia); Arcocha Torres, M. de; Delgado-Bolton, R.; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.37 N° 2 2018 págs. 130 - 138
    Resumen
    La tomografía por emisión de positrones/tomografía computarizada (PET/TC) con 68Ga-PSMA es una técnica de imagen no invasiva para el estudio del cáncer de próstata con incremento de la expresión del antígeno prostático específico de membrana (prostate-specific membrane antigen, PSMA). El PSMA es una proteína transmembrana presente en todos los tejidos prostáticos. El incremento de la expresión de PSMA está presente en varios tumores, aunque su concentración es más elevada en el cáncer de próstata. Casi todos los adenocarcinomas de próstata muestran expresión de PSMA en la mayoría de las lesiones, tanto primarias como metastásicas. Estudios inmunohistoquímicos han demostrado que la expresión de PSMA está incrementada en pacientes con tumores desdiferenciados, metastásicos u hormonorrefractarios. Más aún, el nivel de expresión del PSMA tiene un valor pronóstico para la evolución de la enfermedad. La tomografía por emisión de positrones proporciona una medida de la distribución tridimensional del 68Ga-PSMA, obteniendo imágenes semicuantitativas que permiten valorar de forma no invasiva la expresión de PSMA.
  • Autores: García Velloso, María José (Autor de correspondencia); Rodríguez Fraile, María Macarena
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.37 N° 2 2018 págs. 71 - 72
  • Autores: Prieto Azcárate, Elena; García Velloso, María José; Rodríguez Fraile, María Macarena; et al.
    Revista: PHYSICA MEDICA
    ISSN: 1120-1797 Vol.46 2018 págs. 134 - 139
    Resumen
    A significant radiation dose reduction of 28.7% was reached. Despite a slight reduction in image quality, the new regime was successfully implemented with readers reporting unchanged clinical confidence
  • Autores: Reynés-Llompart, G.; Gámez-Cenzano, C.; Vercher-Conejero, J. L.; et al.
    Revista: MEDICAL PHYSICS
    ISSN: 0094-2405 Vol.45 N° 7 2018 págs. 3214 - 3222
    Resumen
    Introduction: The aim of this study was to evaluate the behavior of a penalized-likelihood image reconstruction method (Q.Clear) under different count statistics and lesion-to-background ratios (LBR) on a BGO scanner, in order to obtain an optimum penalization factor (ß value) to study and optimize for different acquisition protocols and clinical goals. Methods: Both phantom and patient images were evaluated. Data from an image quality phantom were acquired using different Lesion-to-Background ratios and acquisition times. Then, each series of the phantom was reconstructed using ß values between 50 and 500, at intervals of 50. Hot and cold contrasts were obtained, as well as background variability and contrast-to-noise ratio (CNR). Fifteen 18 F-FDG patients (five brain scans and 10 torso acquisitions) were acquired and reconstructed using the same ß values as in the phantom reconstructions. From each lesion in the torso acquisition, noise, contrast, and signal-to-noise ratio (SNR) were computed. Image quality was assessed by two different nuclear medicine physicians. Additionally, the behaviors of 12 different textural indices were studied over 20 different lesions. Results: Q.Clear quantification and optimization in patient studies depends on the activity concentration as well as on the lesion size. In the studied range, an increase on ß is translated in a decrease in lesion contrast and noise. The net product is an overall increase in the SNR, presenting a tendency to a steady value similar to the CNR in phantom data. As the activity concentration or the sphere size increase the optimal ß increases, similar results are obtained from clinical data. From the subjective quality assessment, the optimal ß value for torso scans is in a range between 300 and 400, and from 100 to 200 for brain scans. For the recommended torso ß values, texture indices present coefficients of variation below 10%. Conclusions: Our phantom and patients demonstrate that improvement of CNR and SNR of Q.Clear algorithm which depends on the studied conditions and the penalization factor. Using the Q.Clear reconstruction algorithm in a BGO scanner, a ß value of 350 and 200 appears to be the optimal value for 18F-FDG oncology and brain PET/CT, respectively.
  • Autores: Morales Lozano, María Isabel; Perdomo Zelaya, Carolina María; Grisanti Vollbracht, Fabiana Lucrecia; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.45 N° Supl. 1 2018 págs. S88 - S89
  • Autores: Grisanti Vollbracht, Fabiana Lucrecia; García García, Berta; Morales Lozano, María Isabel; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.37 N° Supl 1 2018 págs. 87
  • Autores: Marti Climent, Josep María; Morán Velasco, Verónica; Mota, M. L.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.45 2018 págs. S733
  • Autores: Vaello, R. M.; Reynes-Llompart, G.; Mateo-Navarro, D.; et al.
    Revista: RADIOTHERAPY AND ONCOLOGY
    ISSN: 0167-8140 Vol.127 N° Supl.1 2018 págs. S1217 - S1218
  • Autores: Reynes-Llompart, G.; Martin-Vaello, R.; Notta, P. ; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.45 N° Supl. 1 2018 págs. S706 - S707
  • Autores: Prieto Azcárate, Elena; Aguilar Redondo, Pedro Borja; Morán Velasco, Verónica; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.45 N° Supl. 1 2018 págs. S312 - S313
  • Autores: Marti Climent, Josep María; Prieto Azcárate, Elena; Morán Velasco, Verónica; et al.
    Libro: Protección radiológica en una instalación de protonterapia
    ISSN: 978-84-313-3817-6 2022 págs. 205 - 220
  • Autores: Irazola Rosales, Leticia; Morán Velasco, Verónica; Bermúdez Luna, Rocío; et al.
    Libro: Protección radiológica en una instalación de protonterapia
    ISSN: 978-84-313-3817-6 2022 págs. 277 - 294
  • Autores: García Velloso, María José; Sancho Rodriguez, Lidia; Bronte Viedma, Angela
    Libro: Ecografía en la Paciente con Cáncer Ginecológico
    ISSN: 9788491108702 (Versión impresa + Versión digital) N° 1a ed. 2022 págs. 163- 172
  • Autores: Marti Climent, Josep María; Prieto Azcárate, Elena; Morán Velasco, Verónica; et al.
    Libro: Tratado de Medicina Nuclear en la práctica clínica
    ISSN: 948-84-7885-661-7 2019 págs. 21-39

Proyectos desde 2018

  • Título: CSNuclear Actividades 2021
    Código de expediente: CSNuclear Actividades 2021
    Investigador principal: JOSEP MARIA MARTI CLIMENT.
    Financiador: CONSEJO DE SEGURIDAD NUCLEAR
    Convocatoria: 2021 CSN Ayudas para divulgación relacionadas con la seguridad nuclear
    Fecha de inicio: 22-12-2021
    Fecha fin: 21-12-2022
    Importe concedido: 7.500,00€
    Otros fondos: -
  • Título: Longitudinal immunogenomic profiling of tumor and immune cells for minimally-invasive detection of early multiple myeloma
    Código de expediente: PI20/00048
    Investigador principal: BRUNO DAVID LOURENCO PAIVA.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2020 AES Proyectos de investigación
    Fecha de inicio: 01-01-2021
    Fecha fin: 31-12-2023
    Importe concedido: 309.457,50€
    Otros fondos: Fondos FEDER
  • Título: Registro prospectivo de hipofraccionamiento con fotonterapia y protonterapia con sobreimpresion en zona GaPSMA positiva en el rescate tras prostatectomia
    Código de expediente: pi20/01598
    Investigador principal: FELIX MAURICIO CAMBEIRO VAZQUEZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2020 AES Proyectos de investigación
    Fecha de inicio: 01-01-2021
    Fecha fin: 31-12-2023
    Importe concedido: 68.970,00€
    Otros fondos: Fondos FEDER
  • Título: Optimización de la radiembolización hepática mediante un modelo de simulación computacional
    Código de expediente: PI18/00692
    Investigador principal: JOSE IGNACIO BILBAO JAUREGUIZAR, MARIA MACARENA RODRIGUEZ FRAILE.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: AES2018 PI
    Fecha de inicio: 01-01-2019
    Fecha fin: 31-12-2022
    Importe concedido: 59.290,00€
    Otros fondos: Fondos FEDER
  • Título: Validación de los microRNAs plasmáticos como biomarcadores de la enfermedad de Alzheimer: estudio clínico, de neuroimagen y genética molecular.
    Código de expediente: 97/2018
    Investigador principal: MARTA FERNANDEZ MATARRUBIA.
    Financiador: GOBIERNO DE NAVARRA. DEPARTAMENTO DE SALUD
    Convocatoria: 2018 PROYECTOS DE I+D EN SALUD
    Fecha de inicio: 01-01-2019
    Fecha fin: 05-10-2021
    Importe concedido: 69.058,65€
    Otros fondos: Fondos FEDER
  • Título: Nueva estrategia terapéutica para evitar el escape inmune en cáncer de pulmón metastásico mediante el bloqueo combinado de PD-1 e Id1
    Código de expediente: 74/2017
    Investigador principal: IGNACIO GIL BAZO.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2017 GN SALUD
    Fecha de inicio: 01-01-2018
    Fecha fin: 15-12-2020
    Importe concedido: 90.000,00€
    Otros fondos: Fondos FEDER
  • Título: ARTERITIS CÉL. GIGANTES: PREVALENCIA VASCULITIS EXTRACRANEAL
    Investigador principal: JOSE ANGEL RICHTER ECHEVARRIA, JAVIER IGNACIO ARBIZU LOSTAO
    Fecha de inicio: 12-12-2019
    Fecha fin: 12-12-2020
    Importe: 0
    Otros fondos: -
  • Título: ARTERITIS CÉL. GIGANTES: PREVALENCIA VASCULITIS EXTRACRANEAL
    Investigador principal: JOSE ANGEL RICHTER ECHEVARRIA
    Fecha de inicio: 06-11-2019
    Fecha fin: 06-11-2021
    Importe: 0
    Otros fondos: -
  • Título: IPA Customer Use Testing-SPECT Release VB22
    Investigador principal: JOSE ANGEL RICHTER ECHEVARRIA, JOSE ANGEL RICHTER ECHEVARRIA
    Fecha de inicio: 06-06-2019
    Fecha fin: 05-06-2020
    Importe: 0
    Otros fondos: -